Chapter 77: The scheming financial institutions
“We didn’t talk too much about anything substantive. Maybe it was because it was our first meeting, so we mainly chatted.”
Reply On the way to the sea, Chen Yuanguang said this when faced with Lin Jia's inquiry.
After the interview with Lin Qinghua ended, the atmosphere of the family dinner was obviously much more harmonious.
After Lin’s mother learned that the person Lin Jia found in Jiang University was Chen Yuanguang, she quickly realized that there was no better person.
Chen Yuanguang is a member of the wealthy generation, and his entrepreneurial direction is the technological innovation most advocated by the country. He has no original sin, and there is no family power to restrict the development of the company. In just over a year, the valuation has exceeded 10 billion.
The two met in college. At that time, Chen Yuanguang had not yet made a fortune, and their emotional foundation was deep enough. In Mother Lin's opinion, it was a perfect match. His enthusiasm almost made Chen Yuanguang treat him as his own son.
“Really?” Lin Jia asked. Because he went home for the holidays, Lin Jia abandoned his daily professional style and wore a dark blue dress, showing off his ladylike style.
Lin Jia obviously didn't believe it. In her impression, Lin Qinghua was very cunning and would not let go of the opportunity to investigate Chen Yuanguang so easily.
Chen Yuanguang said: "There is really nothing substantial to talk about." He felt that if the scene happened again, Lin Jia would have to have a big quarrel with her father again.
When Lin Jia saw that Chen Yuanguang was unwilling to say it, he was not too persistent: "If you don't want to say it, forget it.
In the end, we chose the Marriott Hotel for this investor conference. It has the largest venue and can accommodate two thousand taels. Hundreds of people.”
“It’s great to see so many top investors from all over the country here.
I believe everyone has received an introduction to Guangjia Technology before coming here, including Part of the data from our first phase of clinical trials and analysis conclusions from frontline doctors
Everyone has a preliminary understanding of what Light Armor Technology is going to do. Our current core product is mainly human hibernation technology, to be precise. It is said to be a short-term human hibernation technology. The longest experimenter hibernated so far
Our current round of funding is mainly to conduct clinical trials around the world and obtain sales licenses.
Human hibernation technology has particularly significant effects in areas such as analgesia, some mental illnesses, and hyperthermia, and it eliminates the side effects of other drugs.
It can not only be used in the medical field, but also in aerospace and other fields. This is our follow-up exploration direction.
The valuation of this current round of financing is second, and we need partners who can help us develop the global market.
I can say clearly that this round of fundraising will be the last round of fundraising before Guangjia Technology goes public. The first round of clinical trials will end this year, and the second round of clinical trials will be approved soon. will be approved. After approval, we will promote Guangjia Technology to be listed on the Science and Technology Innovation Board.
The funds raised in the listing round will mainly be used for research and development, because currently our research on human hibernation technology is still at a very basic level. Controlling hibernation time, long-term human hibernation, and even human cryopreservation will all This is our research direction.”
Chen Yuanguang was wearing a suit and a red plaid tie. This outfit was customized by Lin Jia who took him to the old master in Shen Hai Lane two months ago. .
After getting the clothes, Lin Jia lamented that he had good taste, and wearing them on Chen Yuanguang completely highlighted his calm and calm temperament.
There was no trace of Chen Yuanguang at all. He was only in his early twenties.
More than a thousand people came to the venue, and the venue that could hold 2,000 people didn't look empty at all.
When Chen Yuanguang talked about it, everyone was taking note of it. This is first-hand information.
It will be listed in the next round, Chen Yuanguang said so firmly, combined with the fact that SDIC is the second largest shareholder behind it, which means that investment means profit.
Unlike some companies, which are well-known, have revenue, profits and a story, but they have raised 22 rounds of financing and are about to use up 26 English letters.
This is also a devastation to investment institutions. Their shares are constantly diluted in rounds of financing, and they can’t make much money if they invest early. It is still good like Guangjia Technology. Even if it is listed on the A-share market, it can still make money. A company with real technology like Guangjia Technology can definitely become popular if it is listed on the big A-share market.
Therefore, when Chen Yuanguang said that this was the last round of financing before listing, the eyes of the financial elites in the audience shone.
“This round of financing plans to sell 15% of the shares and introduce up to five investment institutions, with uneven shares.
The valuation of this round starts at US$10 billion. What everyone needs is Write down your valuation of Guangjia Technology, how many shares you hope to invest, and what help you can provide in clinical trials.
We have left paper and pen for everyone at each position. , please remember to sign the name of the company after writing it, and then provide it to the service staff.”
After Chen Yuanguang finished explaining the valuation, there was a lot of discussion in the audience.
"I heard that the valuation of the last round was not 10 billion RMB? This round the RMB has been directly converted into US dollars?"
"In other words, this round will raise 1.5 billion US dollars for overseas clinical trials? In major regions like American, the European Union, ASEAN, and East Asia, it will take almost 1 billion U.S. dollars to stop it.”
“More than that, you have to consider that it affects the interests of too many pharmaceutical companies, and you must know that analgesics. The global market size is as high as 90 billion US dollars, and the shares it sells are not enough to get overseas regulators to give them the green light.
It can take two or three years, especially those of Amerikan and the European Union. A region with a strong pharmaceutical industry.
Dr. Chen is very strong in the technical field, but he is still not decisive enough in making profits.
I would say that we must capture at least 30% of the market share in this round, and another 30% after clinical trials, so that we can conquer cities and territories around the world. ”
No matter which country will give priority to protecting its own industry, Amerikan, which is known for its free trade, has done a much more direct job in protecting its own industry than China, forcing Neon to open its door to Amerikan’s semiconductor industry. , forcing American companies not to sell high-tech products to China, and helping General Electric acquire Alstom.
Many times, when Chinese companies want to go overseas, they have to introduce overseas investors, and pure state-owned assets cannot defeat them. Overseas trade protection policy.
Huawei also has to give up profits, but they give up profits to the overseas dealer system, not by introducing investors.
“10 billion US dollars, this valuation is too high. It’s amazing that a company that has been established for more than a year can enjoy such a high valuation. ”
"Will you vote?"
"I won't vote."
"I won't vote either."
"What will you write on the paper if you don't vote?"< br>
“I tried writing a price lower than 10 billion U.S. dollars, and it came.”
"Then I'll write it and give it a try."
This is a zero-sum game, and everyone is scheming.
Is ten billion US dollars too much? The market for analgesics alone in China is close to 20 billion RMB. Adding in other application areas, technological advantages, monopoly business, and imminent launch, it is obviously not much.
(End of this chapter)